Shareholders' Deficit (Details Textual)			1 Months Ended							12 Months Ended
	Jul. 16, 2018	Jun. 06, 2018 USD ($) Individuals $ / shares shares	Jul. 18, 2019 shares	Mar. 31, 2019 USD ($) Consultants $ / shares shares	Dec. 31, 2018 USD ($) Consultants $ / shares shares	Sep. 21, 2018 USD ($)	Aug. 31, 2018 USD ($) $ / shares shares	Aug. 16, 2018	Jul. 18, 2018 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) Transactions $ / shares shares	Dec. 31, 2018 USD ($) Transactions $ / shares shares	Dec. 31, 2017 USD ($)	Jul. 13, 2018 $ / shares	Jan. 03, 2018 shares	Oct. 27, 2017 $ / shares	May 22, 2017 $ / shares	Jan. 01, 2016 shares	Sep. 04, 2014 shares	Sep. 02, 2014 shares
Shareholders' Deficit (Textual)
Grants per share | $ / shares													$ 0.50		$ 0.50	$ 0.75
Risk-free interest rate						2.95%
Expected life (in years)						4 years 9 months 25 days
Expected volatility rate						298.82%
Expected dividend yield						$ 0
Aggregate grant date fair value of warrants issued										$ 54,257	$ 130,306
Gross proceeds									$ 1,999,590
Net proceeds									1,774,690
Repricing date, description								(1) the exercise price of the Series A Warrants issued to the investors and the placement agent was reduced from $0.25 to $0.2233, and (2) the number of Series B Warrants issuable was set at 2,745,757 for the investors and 219,660 for the placement agent.
Legal fees									15,000
Placement agent fees									$ 209,900
Authorized shares of common stock | shares					500,000,000					500,000,000	500,000,000
Preferred shares | shares																			20,000,000
Fair value of warrant										$ 54,257	$ 296,447
Proceeds from warrants excercise										$ 275
Iconic [Member]
Shareholders' Deficit (Textual)
Stock warrants maturity date, description										Company agreed to extend the maturity date of the $550k Note, the $50k Note, the $111k Note and the $357.5k Note until December 31, 2020 in exchange for (i) a new five-year warrant to Iconic to purchase 1,907,143 shares at an exercise price of $0.14 per share, (ii) extension of the expiration date on 12,586,111 warrants held by Iconic until January 1, 2025, (iii) repricing of the exercise price 3,508,333 warrants held by Iconic from various prices above $0.50 to $0.25, (iv) a reduction of the conversion price of the $111k Note from $0.35 to $0.15 and of the $357.5k Note from $0.20 to $0.15, and (v) the Company agreed to allow a one-time conversion of up to $30,000 on the $111k Note at a reduced conversion rate.
Dr. Dent [Member]
Shareholders' Deficit (Textual)
Risk-free interest rate										1.69%
Expected life (in years)										5 years
Expected volatility rate										119.72%
Aggregate grant date fair value of warrants issued										$ 133,943	$ 66,572
Exercise price | $ / shares										$ 0.065
Stock warrants maturity date, description										The maturity date on all of the above notes until December 31, 2020 in exchange for (i) a new five-year warrant to purchase 1,157,143 shares of common stock at an exercise price of $0.014 per share, and (ii) an extension of the expiration date on the 2018 Dr. Dent Warrant from February 12, 2023 to January 1, 2025.
Private Placement [Member]
Shareholders' Deficit (Textual)
Common shares, issued | shares					3,534,891						3,534,891
Proceeds from sale of stock										$ 670,000	$ 417,500
Sale of stock, shares | shares										3,239,924	3,534,891
Warrants to purchase shares of common stock | shares										1,619,962	2,649,798
Exercise price | $ / shares									$ 0.0001
Number of private placement transactions | Transactions										8	6
Warrant terms										5 years	5 years
Securities purchase agreement, description	(1) an aggregate of 3,900,000 shares of the Company's common stock, par value $0.0001 per share, (2) Pre-Funded Warrants to purchase an aggregate of 4,100,000 shares of Company common stock with an exercise price of $0.0001 and a five-year life, (3) Series A Warrants to purchase 8,000,000 shares of Company common stock with an exercise price of $0.25 per share, subject to anti-dilution and other adjustment as described below, and a term of five years, and (4) Series B Warrants to purchase up to a maximum of 17,000,000 shares of Company common stock, subject to adjustment as described below, at a fixed exercise price of $0.0001.
Six Separate Private Placement [Member]
Shareholders' Deficit (Textual)
Proceeds from sale of stock											$ 3,534,891
Warrants to purchase shares of common stock | shares											2,649,798
Warrant terms											5 years
Eight Separate Private Placement [Member]
Shareholders' Deficit (Textual)
Proceeds from sale of stock										$ 3,239,924
Warrants to purchase shares of common stock | shares										1,619,962
Exercise price | $ / shares										$ 0.50
Warrant terms										5 years
Employee Equity Incentive Plan [Member]
Shareholders' Deficit (Textual)
Common stock issued for services, shares | shares										15,503,680
Unrecognized stock compensation										$ 88,045
Stock based compensation recognized for grants										86,523	$ 28,678
Employee Stock Option [Member]
Shareholders' Deficit (Textual)
Stock based compensation recognized for grants										$ 127,010	$ 73,954
Minimum [Member]
Shareholders' Deficit (Textual)
Risk-free interest rate										1.54%	2.32%
Expected life (in years)										3 years	3 years
Expected volatility rate										118.60%	261.18%
Minimum [Member] | Private Placement [Member]
Shareholders' Deficit (Textual)
Sale of stock, per share | $ / shares					$ 0.085					$ 0.12	$ 0.085
Exercise price | $ / shares					0.15					0.22	0.15
Minimum [Member] | Six Separate Private Placement [Member]
Shareholders' Deficit (Textual)
Exercise price | $ / shares					0.15						$ 0.15
Minimum [Member] | Eight Separate Private Placement [Member]
Shareholders' Deficit (Textual)
Exercise price | $ / shares										$ 0.40
Maximum [Member]
Shareholders' Deficit (Textual)
Risk-free interest rate										2.52%	2.93%
Expected life (in years)										5 years	5 years
Expected volatility rate										216.35%	308.60%
Maximum [Member] | Private Placement [Member]
Shareholders' Deficit (Textual)
Sale of stock, per share | $ / shares					0.35					$ 0.30	$ 0.35
Exercise price | $ / shares					0.45					0.40	0.45
Maximum [Member] | Six Separate Private Placement [Member]
Shareholders' Deficit (Textual)
Exercise price | $ / shares					$ 0.45						$ 0.45
Maximum [Member] | Eight Separate Private Placement [Member]
Shareholders' Deficit (Textual)
Exercise price | $ / shares										$ 0.22
Series A and Series B Warrants [Member]
Shareholders' Deficit (Textual)
Warrants to purchase shares of common stock | shares									1,360,000
Loss on change in fair value of derivative liabilities						385,856
Series A Warrants [Member]
Shareholders' Deficit (Textual)
Issued warrants | shares										5,864,843	27,635,819
Risk-free interest rate										2.77%
Expected life (in years)										5 years
Expected volatility rate										288.00%
Expected dividend yield										$ 0
Aggregate grant date fair value of warrants issued										920,668	$ 4,645,446	$ 4,645,446
Net proceeds										$ 1,774,690
Placement agent warrants issued | shares			640,000
Warrants to purchase shares of common stock | shares										250,000
Exercise price | $ / shares										$ 0.50
Warrant terms										3 years
Warrants, description										(1) because the Series A Warrants were not settled at a fixed price, these instruments did not qualify for equity classification and were recorded as derivative financial instruments with an inception date fair value of $1,984,722, (2) because the Series B Warrants were not settled into a fixed number of shares, these instruments did not qualify for equity classification and were recorded as derivative financial instruments with an inception date fair value of $412,794, (3) the Pre-Funded Warrants were settled into a fixed number of shares at a fixed price and were classified as equity with an inception date fair value of $942,988.
Financing cost										$ 623,216
Proceeds from warrants excercise										$ 275	$ 0
Warrants exercised | shares					2,000,001					4,937,745	2,000,001
Common Stock Issuable [Member]
Shareholders' Deficit (Textual)
Fair value of warrant
Additional Paid-in Capital [Member]
Shareholders' Deficit (Textual)
Fair value of warrant										54,257	296,447
Common Stock [Member]
Shareholders' Deficit (Textual)
Fair value of warrant
Series B Warrants [Member]
Shareholders' Deficit (Textual)
Derivative liabilities						711,692
Series A Warrants [Member]
Shareholders' Deficit (Textual)
Derivative liabilities						$ 2,071,680
Five-year warrants [Member]
Shareholders' Deficit (Textual)
Issued warrants | shares		600,000
Exercise price | $ / shares		$ 0.15
Warrant terms		5 years
Number of individuals | Individuals		2
Fair value of warrant		$ 94,844
Five-year warrants [Member] | Consulting Service [Member]
Shareholders' Deficit (Textual)
Issued warrants | shares							400,000
Exercise price | $ / shares							$ 0.35
Warrant terms							5 years
Fair value of warrant							$ 145,861
Three-year warrants [Member] | Consulting Service [Member]
Shareholders' Deficit (Textual)
Issued warrants | shares				180,000	240,000
Exercise price | $ / shares				$ 0.35	$ 0.20						$ 0.20
Warrant terms				3 years	3 years
Fair value of warrant				$ 54,257	$ 35,462
Number of consultants | Consultants				2	2
Warrant Three [Member] | Eight Separate Private Placement [Member]
Shareholders' Deficit (Textual)
Warrants to purchase shares of common stock | shares										250,000
Common Stock [Member]
Shareholders' Deficit (Textual)
Sale of stock, shares | shares										479,762
Common Stock, description										The funds were received and shares were issued in January and February 2020.
Obligated to issue shares of common stock											$ 0
Stock subscription agreements										$ 59,000
Common Stock [Member] | Investment Agreement [Member]
Shareholders' Deficit (Textual)
Common shares, issued | shares					2,440,337					5,074,068	2,440,337
Net proceeds										$ 929,986	$ 440,523
Common Stock [Member] | Employee Equity Incentives Plans [Member]
Shareholders' Deficit (Textual)
Common shares, issued | shares																	15,503,680
Common Stock [Member] | Minimum [Member]
Shareholders' Deficit (Textual)
Authorized shares of common stock | shares														500,000,000
Common Stock [Member] | Maximum [Member]
Shareholders' Deficit (Textual)
Authorized shares of common stock | shares														230,000,000
Series A Convertible Preferred Stock [Member]
Shareholders' Deficit (Textual)
Preferred shares | shares																		20,000,000